AlphAIAlphAI — Financial news for AI agents
lw.comOCT 301 min read$ASPE

Latham Advises on Aspen Neuroscience’s US$140.6 Million IPO

Aspen Neuroscience (ASPE) priced its IPO at $15 per share, raising $140.6M from 9.375M shares. The company may issue 1.406M more shares within 30 days. Latham & Watkins advised the underwriters.

Original reporting
lw.com
Published Oct 30, 2026, 7:17 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 31, 2026, 6:12 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Latham Advises on Aspen Neuroscience’s US$140.6 Million IPO — source image
Source · lw.com
Decision brief

The 30-second read

$ASPEBullishHigh
01

Why it matters

The IPO pricing provides a clear entry point for investors and may set a valuation benchmark for similar biotech firms.

02

Market read

First‑day pricing of a $140 M biotech IPO offers immediate trading opportunity and may influence sector sentiment.

03

What to watch

Potential regulatory or clinical trial risks could temper enthusiasm despite the capital raise.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

Aspen Neuroscience is a clinical‑stage company developing autologous cell therapies for Parkinson’s disease.

Company-level read

Ticker impact

$ASPEBullishHigh confidence
Context

Aspen Neuroscience announced pricing of its IPO at $15 per share, raising $140.6 million.

Expected impact

upward pressure as investors allocate capital to the offering

Evidence & confidence

First report of a sizable $140 M biotech IPO; market participants can act on the pricing immediately.

Market effects

Sector

Adds capital to the regenerative‑medicine biotech sector and may lift peer valuations.

Regional

U.S. biotech market sees fresh inflow; no broader regional effect.

Global

Limited to investors tracking U.S. biotech IPO pipeline.

Counterpoint

What could challenge this read

If demand for biotech IPOs wanes, the offering could price below expectations.

Key entities

  • law_firm
    Latham & Watkins LLP

    Legal counsel representing the underwriters.

Read at source← All news

StoryAspen Neuroscience prices $15 IPO, raising $140.6 million

Also covered by

5 outlets

Related articles

OCT 30
$ASPEHighAI 8/10

Aspen Neuroscience (ASPE) raises $140.6 million in Nasdaq IPO at $15

Aspen Neuroscience (ASPE) raised $140.6M in its Nasdaq IPO, pricing shares at $15. The proceeds will fund its Parkinson's disease cell therapy pipeline. Five banks led the offering, aiming to diversify its shareholder base. The company's clinical pipeline is now under increased scrutiny from analysts and shareholders.

247wallst.com2 min
OCT 30
$ASPEHighAI 9/10

Aspen raises a $140M IPO in pursuit of a cell therapy for Parkinson’s

Aspen Neuroscience raised $140.6M in its IPO, selling 9.4M shares at $15 each. The company's cell therapy, sasineprocel, aims to treat Parkinson's by replenishing dopamine-producing neurons. It will trade under 'ASPE'. Early trial data showed potential improvements and a favorable safety profile. Long-term data is expected in 2028, with a Phase 3 study planned by the end of 2024. Aspen claims its personalized approach could be safer and more effective than donor-derived therapies.

finance.yahoo.com2 min